Investigational drug · Phase 3
Rina-S
Also called: PRO1184, GEN1184, Rinatabart sesutecan
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
9
Any phase or sponsor naming "Rina-S"
First trial start
2022
Dec 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rina-S", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Platinum-sensitive Ovarian Cancer
- PSOC
- Gastrointestinal Cancers
- Platinum-Sensitive Ovarian Cancer
- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Rina-S" as an intervention, largest first.
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Recruiting
GenmabIndustry
NCT05579366 · 952 participants (planned) · Start Dec 7, 2022 · Primary completion Dec 2028
Drug: Rina-S; Carboplatin and 4 more · For: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma and 13 more
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 67 sites in all
GenmabIndustry
NCT07564141 · 688 participants (planned) · Start Aug 28, 2026 · Primary completion Dec 2029
Drug: Rina-S; Bevacizumab and 4 more · For: Platinum-Sensitive Ovarian Cancer; Ovarian Cancer
Sites: Duarte, California; Danbury, Connecticut; Tigard, Oregon · 12 sites in all
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerPivotal-lookingRecruiting
GenmabIndustry
NCT07166094 · 660 participants (planned) · Start Nov 28, 2025 · Primary completion Aug 2029
Drug: Rina-S; IC · For: Endometrial Cancer; Recurrent or Progressive Endometrial Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Irvine, California · 178 sites in all
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerPivotal-lookingNot yet recruiting
GenmabIndustry
NCT07859215 · 602 participants (planned) · Start Nov 2026 · Primary completion Mar 2030
Drug: Rina-S; Bevacizumab · For: Ovarian Cancer
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPivotal-lookingActive, not recruiting
GenmabIndustry
NCT06619236 · 584 participants · Start Feb 7, 2025 · Primary completion Aug 18, 2026
Drug: Rina-S; Paclitaxel and 3 more · For: Platinum-resistant Ovarian Cancer
Sites: Anchorage, Alaska; Scottsdale, Arizona; Tucson, Arizona · 177 sites in all
GenmabIndustry
NCT07225270 · 544 participants (planned) · Start Apr 3, 2026 · Primary completion Oct 2028
Drug: Rina-S; Bevacizumab · For: Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC
Sites: Sacramento, California; Hartford, Connecticut; Miami, Florida · 69 sites in all
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerRecruiting
GenmabIndustry
NCT07288177 · 240 participants (planned) · Start Jan 30, 2026 · Primary completion Nov 22, 2027
Drug: Rina-S · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Fountain Valley, California; Irvine, California; San Diego, California · 102 sites in all
GenmabIndustry
NCT07539311 · 160 participants (planned) · Start May 11, 2026 · Primary completion Sep 2028
Drug: Rina-S · For: Gastrointestinal Cancers
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 28 sites in all
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaPivotal-lookingRecruiting
GenmabIndustry
NCT07604766 · 82 participants (planned) · Start Jun 26, 2026 · Primary completion Sep 2027
Drug: Rina-S; Paclitaxel and 3 more · For: Platinum-resistant Ovarian Cancer
Sites: Changchun, China; Changsha, China; Chengdu, China · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.